Lexicon Welcomes Scott Coiante As New Chief Financial Officer

Lexicon Pharmaceuticals, Inc. announced today that Scott Coiante has been appointed Senior Vice President and Chief Financial Officer, effective January 2, 2025. With over 35 years of finance experience in the life sciences and pharmaceutical sectors, Mr. Coiante brings extensive expertise to Lexicon. 

Mike Exton, Ph.D., chief executive officer and director of Lexicon, commented, “We are thrilled to welcome Scott as our new chief financial officer. His extensive experience aligns with our ongoing shift in strategy to focus on high-impact therapeutic areas. As we continue to refine and execute our Lead to Succeed strategy, Scott will be instrumental in steering Lexicon toward sustainable growth and creating significant value for our shareholders while advancing our R&D programs.”

Before joining the company, he served as Senior Vice President, CFO, and Treasurer at Agile Therapeutics, having two separate tenures: from 2011 to 2019 and from August 2023 to August 2024. He oversaw financial operations, business development, and fundraising efforts at Agile Therapeutics.

Mr. Coiante said in a statement, “I am pleased to join Lexicon at this pivotal moment for the company and eager to contribute to its ambitious mission of transforming patients’ lives with innovative medicines. I look forward to working with the talented team at Lexicon to drive financial strategies that align with the Company’s vision, support its promising R&D pipeline programs and drive growth.”

Before his role at Agile Therapeutics, Mr. Coiante was Senior Vice President, CFO, Treasurer, and Secretary at Aprea Therapeutics. He held several senior financial positions at Medarex Inc., where he helped manage the company’s transition following its acquisition by Bristol-Myers Squibb. He earned his Bachelor of Science degree from Villanova University.